Tucatinib Patent Expiration
Tucatinib is Used for treating advanced or metastatic colorectal cancer and breast cancer that is HER2-positive or overexpressing. It was first introduced by Seagen Inc
Tucatinib Patents
Given below is the list of patents protecting Tucatinib, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Tukysa | US11207324 | Treatment of HER2 positive cancers | Apr 27, 2038 | Seagen |
| Tukysa | US11666572 | Treatment of HER2 positive cancers | Apr 27, 2038 | Seagen |
| Tukysa | US12048698 | Treatment of HER2 positive cancers | Apr 27, 2038 | Seagen |
| Tukysa | US8648087 | N4-phenyl-quinazoline-4-amine derivatives and related compounds as ErbB type I receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases | Apr 17, 2034 | Seagen |
| Tukysa | US11504370 | Treatment of brain cancer | Mar 25, 2033 | Seagen |
| Tukysa | US9457093 | Solid dispersions of a ERB2 (HER2) inhibitor | Oct 12, 2032 | Seagen |
| Tukysa | US9693989 | N4-phenyl-quinazoline-4-amine derivatives and related compounds as ErbB type I receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases | May 09, 2027 | Seagen |
| Tukysa | US7452895 | Quinazoline analogs as receptor tyrosine kinase inhibitors | Nov 16, 2026 | Seagen |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or
decrease the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that
drug. Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in
the patent process of
the drug which can give an idea of how early a drug's generic could be available. The next
section provides a list
of recent legal activities on Tucatinib's patents.
Latest Legal Activities on Tucatinib's Patents
Given below is the list recent legal activities going on the following patents of Tucatinib.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Notice of Final Determination -Election Required | 03 Mar, 2026 | US8648087 |
| 37 CFR 1.750 Request for reconsideration | 12 Feb, 2026 | US8648087 |
| Terminal Disclaimer Filed | 02 Feb, 2026 | US8648087 |
| Withdrawal of Application for PTE | 16 Jan, 2026 | US7452895 |
| Notice of Final Determination -Election Required | 16 Jan, 2026 | US9693989 |
| Notice of Final Determination -Election Required | 16 Jan, 2026 | US8648087 |
| Notice of Final Determination -Election Required | 16 Jan, 2026 | US9457093 |
| Withdrawal of Application for PTE | 15 Jan, 2026 | US7452895 |
| Interim Patent Term Extension Granted | 12 Nov, 2025 | US7452895 |
| Requirement for information sent under 37 CFR 1.750 | 19 Sep, 2025 | US7452895 |
Tucatinib's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Tucatinib:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
